Pharmacogenetics: Promise and potential in child and adolescent psychiatry

Child and Adolescent Psychiatric Clinics of North America

Volumn 9, Issue 1, 2000, Pages 23-42

  Anderson, G M ^a   Cook, E H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; EPIPODOPHYLLOTOXIN; FENFLURAMINE; NEUROLEPTIC AGENT; PSYCHEDELIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRASTUZUMAB; TRAZODONE;

ALLELE; ANTINEOPLASTIC ACTIVITY; CHILD PSYCHIATRY; DRUG RESPONSE; ETHNOLOGY; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; MENTAL DISEASE; METHODOLOGY; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROTONIN BLOOD LEVEL;

EID: 0034018242     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1056-4993(18)30134-2     Document Type: Review

References (98)

1. Ando Y. Saka H. Asai G. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan Ann Oncol 9 1998 845 847
2. Anonymous: Pharmacogenomics at work. Nat Biotechnol 16:885, 1998
3. Arranz M.J. Munro J. Sham P. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response Schizophr Res 32 1998 93 99
4. Bathum L. Johansson I. Ingelman-Sundberg M. Ultrarapid metabolism of sparteine: Frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction Pharmacogenetics 8 1998 119 123
5. Bell G. Horita S. Karam J. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus Diabetes 33 1984 176 183
6. Benjamin J. Li L. Patterson C. Population and familial association between the D4 dopamine receptor gene and measures of novelty seeking Nat Genet 12 1996 81 84
7. Billett E.A. Richter M.A. King N. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene Mol Psychiatry 2 1997 403 405
8. Black B. Uhde T.W. Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study J Am Acad Child Adolesc Psychiatry 33 1994 1000 1006
9. Blacker D. Highness JCL Roods L. ApoE-4 and age at onset of Alzheimer’s disease: The NIMH Genetics initiative Neurology 48 1997 139 147
10. Blum K. Noble E.P. Sheridan P.J. Allelic association of human dopamine D2 receptor gene in alcoholism JAMA 263 1990 2055 2060
11. journal Paul CNS drug discovery in the 21st century: From genomics to combinatorial chemistry and back Br J Psychiatry 37 suppl 1999 23 25
12. Castellanos F. Lau E. Tayebi N. Lack of an association between a dopamine-4 receptor polymorphism and attention-deficit/hyperactivity disorder: Genetic and brain morphometric analyses Mol Psychiatry 3 1998 431 434
13. Comings D. Gade R. Muhleman D. No association of a tyrosine hydroxylase gene tetranucleotide repeat polymorphism in autism, Tourette syndrome, or ADHD Biol Psychiatry 37 1995 484 486
14. Cook E. Courchesne R. Lord C. Evidence of linkage between the serotonin transporter and autistic disorder Mol Psychiatry 2 1997 247 250
15. Cook E. Rowlett R. Jaselskis C. Fluoxetine treatment of patients with autism and mental retardation J Am Acad Child Adolesc Psychiatry 31 1992 739 745
16. Cook E. Stein M. Krasowski M. Association of attention deficit disorder and the dopamine transporter gene Am J Hum Genet 56 1995 993 998
17. Crabbe J.C. Belknap J.K. Buck K.J. Genetic animal models of alcohol and drug abuse Science 264 1994 1715 1726
18. Cubells J.F. Rosenheck R. Charney D.S. High plasma dopamine-13-hydroxylase activity associated haplotypes at the DBH locus are more frequent in treatmentrefractory male schizophrenic patients December 1998 Presented at the 37th ACNP Annual Meeting Puerto Rico 14 18
19. Daly G. Hawi Z. Fitzgerald M. Mapping susceptibility loci in attention deficit ahyperactivity disorder: Preferential transmission of parental alleles at DATl, DBH and DRD5 to affected children Mol Psychiatry 4 1999 192 196
20. Dudley C. Keavney B. Casadei B. Prediction of patient responses to antihypertensive drugs suing genetic polymorphism: Investigation of renin-angiotensin system genes J Hypertens 14 1996 259 262
21. Ebstein R.P. Novick O. Umansky R. Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of novelty seeking Nat Genet 12 1996 78 80
22. Emslie G. Rush A. Weinberg W. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression Arch Gen Psychiatry 54 1997 1031 1037
23. Epperson C.N. Anderson G.M. McDougle C.J. Platelet serotonin in breast-feeding infants of mothers receiving sertraline New Engl J Med 336 1997 1189 1190
24. Felix C.A. Walker A.H. Lange B.J. Association of CYP3A4 genotype with treatment-related leukemia Proc Natl Acad Sci US A 95 1998 13176 13181
25. other Ferrari Pharmacogenomics: A new approach to individual therapy of hypertension? Curr Opin Nephrol Hypertens 7 1998 217 222
26. Gelernter J. Goldman D. Risch N. The Al allele at the D2 dopamine receptor gene and alcoholism: A reappraisal JAMA 269 1993 1673 1677
27. Gelernter J. Kranzler H. Satel S.L. No association between D2 dopamine receptor (DRD2) alleles or haplotypes and cocaine dependence or severity of cocaine dependence in european- and african-americans Biolo Psychiatry 45 1999 340 345
28. Gelernter J. Kranzler H.R. Satel S.L. Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia Neuropsychopharmacology 11 1994 195 200
29. Geller B, Cook E: Genetic transmission of serotonin transporter alleles in prepubertal and early adolescent bipolarity. Biol Psychiatry (in press)
30. Gill M. Daly G. Heron S. Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism Mol Psychiatry 2 1997 311 313
31. Greenberg B.D. Tolliver T.J. Huang S.J. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets Am J Med Genet 88 1999 83 87
32. Grice D.E. Leckman J.F. Pauls D.L. Linkage disequilibrium between an allele at the dopamine D4 receptor locus and Tourette syndrome, by the transmissiondisequilibrium test Am J Hum Genet 59 1996 644 652
33. Grisel J.E. Belknap J.K. O’Toole L.A. Quantitative trait loci affecting methamphetamine responses in BXD recombinant inbred mouse strains J Neurosci 17 1997 745 754
34. Hanna G.L. Himle J.A. Curtis G.C. Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder Neuropsychopharmacology 18 1998 102 111
35. Hebebrand J. Nothen M.M. Ziegler A. Nonreplication of linkage disequilibrium between the D4 receptor locus and Tourette syndrome Am J Hum Genet 61 1997 238 239
36. Hinney A. Becker I. Heibult O. Systematic mutation screening of the POMC gene J Clin Endocrinol Metab 83 1998 3737 3741
37. Housman D. Ledley F.D. Why pharmacogenomics? Why now? Nat Biotechnol 16 1998 492 493
38. Itoh K. Inoue K. Yanagiwara S. A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2Cl9 Biol Pharm Bull 22 1999 77 79
39. Kanes S. Dains K. Cipp L. Mapping the genes for haloperidol-induced catalepsy J Pharmacol Exp Ther 277 1996 1016 1025
40. Kang A.M. Palmatier M.A. Kidd K. Global variation of a 40-bp VNTR in the 3′untranslated region of the dopamine transporter gene (SLC6A3) Biological Psychiatry 46 1999 151 160
41. Kawanishi C. Hanihara T. Shimada Y. Lack of association between neuroleptic malignant syndrome and polymorphisms in the 5-HTlA and 5-HT2A receptor genes Am J Psychiatry 155 1998 1275 1277
42. Kelsoe J. Sadovnick A. Kristbjarnarson H. Possible locus for bipolar disorder near the dopamine transporter on chromosome 5 Am J Med Genet (Neuropsychiatr Genet) 67 1996 533 540
43. other Kelsoe Promoter prognostication: The serotonin transporter gene and antidepressant response Mol Psychiatry 3 1998 475 476
44. Klauck S.M. Poutska F. Benner A. Serotonin transporter (5-HTT) gene variants associated with autism? Hum Mol Genet 6 1997 2233 2238
45. other Knapp A note on power approximations for the transmission/disequilibrium test Am J Hum Genet 64 1999 1177 1185
46. Kohn Y. Ebstein R.P. Heresco-Levy U. Dopamine D4 receptor gene polymorphisms: Relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects Eur Neuropsychopharmacol 7 1997 39 43
47. Krebs M.O. Sautel F. Bourdel M.C. Dopamine D3 receptor gene variante and substance abouse in schizophrenia Mol Psychiatry 3 1998 337 341
48. LaHoste G. Swanson J. Wigal S. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder Mol Psychiatry 1 1996 128 131
49. Lappalainen J. Long J.C. Eggert M. Linkage of antisocial alcoholism to the serotonin 5-HTIB receptor gene in 2 populations Arch Gen Psychiatry 55 1998 989 994
50. Laruelle M. Gelernter J. Innis R.B. D2 receptors binding potential is not affected by Taql polymorphism at the D2 receptor gene Mol Psychiatry 3 1998 261 265
51. Lawford B.R. Young R.M. Rowell J.A. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor Al allele Nat Med 1 1995 337 341
52. Leathart J.B. London S.J. Steward A. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles Pharmacogenetics 8 1998 529 541
53. Lerman C. Caporaso N. Main D. Depression and self-medication with nicotine: The modifying influene of the dopamine D4 receptor gene Health Psychol 17 1998 56 62
54. Lesch K.P. Bengel D. Heils A. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region Science 274 1996 1527 1531
55. other Lesch Hallucinations: Psychopathology meets functional genomics Mol Psychiatry 3 1998 278 281
56. Levesque E. Beaulieu M. Green M.D. Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene Pharmacogenetics 7 1997 317 325
57. other Liggett Pharmacogenetics of relevant targets in asthma Clin Exp Allergy 28 suppl 1 1998 77 79
58. Little K.Y. McLaughlin D.P. Zhang L. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels Am J Psychiatry 155 1998 207 213
59. Lundqvist E. Johansson I. Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes Gene 226 1999 327 338
60. MacGowan S.H. Wilcock G.K. Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer’s disease Int J Geriatr Psychiatry 13 1998 625 630
61. Maestrini E. Lai C. Marlow A. Serotonin transporter (5-HTT) and gammaaminobuyric acid receptor subunit beta-3 (GABRB3) gene polymorphisms are not associated with autism in the IMGSA families Am J Med Genet (Neuropsychiatr Genets) 88 1999 492 496
62. Malhotra A. Breier A. Goldman D. Pharmacogenetics of antipsychotic drug response December 1998 Presented at the 37th ACNP Annual Meeting Puerto Rico 14 18
63. Malhotra A.K. Goldman D. Mazzanti C. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics Mol Psychiatry 3 1998 328 332
64. Malhotra A.K. Goldman D. Buchanan R.W. The dopamine D3 receptor (DRD3) ser9Gly polymorphism and schizophrenia: A haplotype relative risk study and association with clozapine response Mol Psychiatry 3 1998 72 75
65. Malhotra A.K. Goldman D. Ozaki N. Clozapine response and the 5HT2C cys23ser polymorphism Neuroreport 7 1996 2100 2102
66. March J.S. Biederman J. Wolkow R. Sertraline in children and adolescents with obsessive-compulsive disorder-a multicenter randomized controlled trial JAMA 280 1998 1752 1756
67. other Marshall Laying the foundations for personalized medicines Nat Biotechnol 15 1997 954 957
68. Martinez D. Gelernter J. Abi-Dargham A. Dopamine transporter polymorphism and function: A brain imaging study December 1998 Presented at the 37th ACNP Annual Meeting Puerto Rico 14 18
69. Masellis M. Basile V. Meltzer H.Y. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients Neuropsychopharmacology 19 1998 123 132
70. Mazzanti C.M. Lappalainen J. Long J.C. Role of the serotonin transporter promoter polymorphism in anxiety-related traits Arch Gen Psychiatry 55 1998 936 940
71. McDougle C. Naylor S. Cohen D. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder Arch Gen Psychiatry 53 1996 1001 1008
72. McDougle C.J. Epperson C.N. Price L.H. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder Mol Psychiatry 3 1998 270 273
73. other Meltzer An overview of the mechanism of action of clozalpine J Clin Psychiatry 55 1994 47 52
74. Meyer U.A. Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism Annu Rev Pharmacol Toxicol 37 1997 269 296
75. Narayan M. Anderson G.M. Cellar J. Serotonin transporter blocking propeties of nefazodone assessed by measurement of platelet serotonin Biol Psychiatry 18 1998 67 71
76. other Nestler Molecular mechanisms of opiate and cocaine addiction Curr Opin Neurobiol 7 1997 713 719
77. Nielsen D.A. Virkkunen M. Lappalainen J. A tryptophan hydroxylase gene marker for suicidality and alcoholism Arch Gen Psychiatry 55 1998 593 602
78. Paul S: CNS drug discovery in the 21st century. From genomics to combinatorial chemistry and back.
79. Paul S.M. Wu X. Liang Y. Molecular strategies to novel antidepressant discovery Skolnick P. Antidepressants: New Pharmacological Strategies 1997 Humana Press Totowa, NJ 235 250
80. Pianezza M.L. Sellers E.M. Tyndale R.F. Nicotine metabolism defect reduces smoking Nature 393 1998 750
81. Poirier J. Sevigny P. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer’s disease J Neur Transm 53 suppl 1998 199 207
82. Riddle M. Scahill L. King R. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder J Am Acad Child Adolesc Psychiatry 31 1992 1062 1069
83. Rietschel M. Naber D. Fimmers R. Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor Neuroreport 8 1997 1999 2003
84. Rowe D. Stever C. Giedinghagen L. Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder Mol Psychiatry 3 1998 419 426
85. other Rubinsztein Apolipoprotein E: A review of its role in lipoprotein metabolism, neuronal growth and repair and as a risk factor for Alzheimer’s disease Psychol Med 25 1995 223 239
86. Sander T. Harms H. Lesch K.P. Association analysis of a regulatory variation of the serotonin transporter Alcohol Clin Exp Res 21 1997 1356 1359
87. Shaikh S. Collier D. Kerwin R.W. Dopamine D4 receptor subtypes and response to clozapine [letter] Lancet 34 1993 116
88. Smalley S. Bailey J. Palmer C. Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder Mol Psychiatry 3 1998 427 430
89. Smeraldi E. Zanardi R. Benedetti F. Polymorphism within the promoter gene and antidepressant efficacy of fluvoxamine Mol Psychiatry 3 1998 508 511
90. Spielman R. Ewens W. The TDT and other family-based tests for linkage disequilibrium and association Am J Hum Genet 59 1996 983 989
91. Spielman R.S. McGinnis R.E. Ewens W.J. Transmission test for linkage disequilibrium: The insulin gene region and insulin-dependent diabetes mellitus (IDDM) Am J Hum Genet 52 1993 506 516
92. Swanson J.M. Sunohara G.A. Kennedy J.L. Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): A family-based approach Mol Psychiatry 3 1998 38 41
93. Terwilliger J. Ott J. A haplotype based ’Haplotype Relative Risk’ approach to detecting allelic associations Hum Hered 42 1992 337 346
94. Tordjman S. Gutneckt L. Carlier M. Serotonin transporter promoter variants in autistic disorder: Genetic transmission, behavioral associations, and relationship to platelet serotonin measures [abstract] Soc Neurosci 24 1999 819
95. other Uhl Molecular genetics of substance abuse vulnerability: A current approach Neuropsychopharmacology 20 1999 3 9
96. Vanyukov M.M. Moss H.B. Gioio A.E. An association between a microsatellite polymorphism at the DRD5 gene and the liability to substance abuse: Pilot study Behav Genet 28 1998 75 82
97. Vincent M. Samani N.J. Gauguier D. A pharmacogenetic approach to blood pressure in Lyon hypertensive rats. A chromosome 2 locus influences the response to a calcium antagonist J Clin Invest 100 1997 2000 2006
98. Waldman I. Rowe D. Abramowitz A. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: Heterogeneity owing to diagnostic subtype and severity Am J Hum Genet 63 1998 1767 1776